Anzeige
Mehr »
Login
Donnerstag, 28.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AG0F | ISIN: SE0006091997 | Ticker-Symbol: 1YR
Frankfurt
28.03.24
09:16 Uhr
0,096 Euro
-0,003
-2,83 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
IMMUNOVIA AB Chart 1 Jahr
5-Tage-Chart
IMMUNOVIA AB 5-Tage-Chart

Aktuelle News zur IMMUNOVIA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
12.03.Immunovia AB: Immunovia announces updated financial calendar178LUND, Sweden, March 12, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq) (IMMNOV: Stockholm), the diagnostics company with the mission to increase pancreatic cancer survival rates through...
► Artikel lesen
21.02.Immunovia reports Q4 results1
21.02.Immunovia AB: Immunovia Publishes Full Year Report for 2023213LUND, Sweden, Feb. 21, 2024 /PRNewswire/ -- October-December 2023 Net sales, which for the quarter only included royal- ties, amounted to kSEK 155 (502).Net earnings were MSEK...
► Artikel lesen
14.02.Immunovia AB: Invitation to Immunovia's Q4 presentation234LUND, Sweden, Feb. 14, 2024 /PRNewswire/ -- Immunovia will publish its full year 2023 results on February 21, 2024 at 8:30 am CET. Analysts, investors and media are invited to a webcast teleconference...
► Artikel lesen
31.01.Immunovia hires new VP for clinical studies1
31.01.Immunovia AB: Immunovia appoints Norma Alonzo Palma as new Vice President of Clinical and Medical Affairs256LUND, Sweden, Jan. 31, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the diagnostics company with the mission to increase pancreatic cancer survival rates through early detection...
► Artikel lesen
04.01.Immunovia AB: Immunovia announces financial calendar for financial year 2024288LUND, Sweden, Jan. 4, 2024 /PRNewswire/ -- Immunovia, a diagnostic company with the vision to revolutionize blood-based diagnostics and survival rates for patients with cancer, announces...
► Artikel lesen
21.11.23Bulletin from the extraordinary general meeting in Immunovia AB349LUND, Sweden, Nov. 21, 2023 /PRNewswire/ -- On 21st November 2023, an extraordinary general meeting ("EGM") was held in Immunovia AB (publ), 556730-4299, at Medicon Village in Lund....
► Artikel lesen
09.11.23Immunovia reports Q3 results5
09.11.23Immunovia AB: Immunovia Publishes Interim Report for January-September 2023215LUND, Sweden, Nov. 9, 2023 /PRNewswire/ -- July-September 2023 Net sales amounted to KSEK 488 (358) divided by sales of tests KSEK 70 (111) and royalties KSEK 418 (247).Net earnings...
► Artikel lesen
07.11.23Immunovia AB: Immunovia successfully completes discovery phase of next-generation test development380LUND, Sweden, Nov. 7, 2023 /PRNewswire/ -- Immunovia (Nasdaq Stockholm: IMMNOV), the diagnostics company focused on early detection of pancreatic cancer, today announced the successful completion...
► Artikel lesen
02.11.23Immunovia AB: Invitation to Immunovia's Q3 presentation248LUND, Sweden, Nov. 2, 2023 /PRNewswire/ -- Immunovia will publish its third quarter 2023 results on November 9, 2023 at 8:30 am CET. Analysts, investors and media are invited to a webcast...
► Artikel lesen
27.10.23CONVENING NOTICE - EXTRAORDINARY GENERAL MEETING IN IMMUNOVIA AB (PUBL)335LUND, SWEDEN, Oct. 27, 2023 /PRNewswire/ -- Immunovia AB (publ), reg. no. 556730-4299 (the "Company"), hereby gives notice that an extraordinary general meeting will take place on Tuesday...
► Artikel lesen
03.10.23Nomination Committee appointed for Immunovia AB (Publ)264LUND, Sweden, Oct. 3, 2023 /PRNewswire/ -- According to the instructions for the Nomination Committee of Immunovia AB (Publ) that were adopted at the Annual General Meeting on May 26, 2023...
► Artikel lesen
30.08.23Immunovia AB: Immunovia Publishes Interim Report for January-June 2023363LUND, Sweden, Aug. 30, 2023 /PRNewswire/ -- April-June 2023 Net sales amounted to kSEK 412 (103) divided by sales of tests kSEK 351 (45) and royalties kSEK 61 (58).Net...
► Artikel lesen
23.08.23Immunovia AB: Invitation to Immunovia's Q2 presentation445LUND, Sweden, Aug. 23, 2023 /PRNewswire/ -- Immunovia will publish its second quarter 2023 results on August 30, 2023 at 8:30 am CET. Analysts, investors and media are invited to a webcast...
► Artikel lesen
19.07.23Immunovia AB: Immunovia announces updated financial calendar434LUND, Sweden, July 19, 2023 /PRNewswire/ -- Immunovia (Nasdaq Stockholm: IMMNOV), the diagnostics company focused on early detection of pancreatic cancer, updates its financial calendar for...
► Artikel lesen
12.07.23Immunovia AB: Immunovia to Significantly Restructure to Focus Resources on its Next-Generation Blood Test for Pancreatic Cancer Detection553LUND, Sweden, July 12, 2023 /PRNewswire/ -- Immunovia (Nasdaq Stockholm: IMMNOV), the diagnostics company focused on early detection of pancreatic cancer, today announced plans to restructure...
► Artikel lesen
09.06.23Immunovia AB: Chief Executive Officer, Jeff Borcherding, buys Immunovia shares409LUND, Sweden, June 9, 2023 /PRNewswire/ -- Immunovia AB (Nasdaq: IMMNOV) announces today that Jeff Borcherding, CEO of Immunovia, has purchased 350 000 shares for approximately 670 KSEK.His...
► Artikel lesen
31.05.23Change in number of shares and votes in Immunovia AB (publ)402LUND, Sweden, May 31, 2023 /PRNewswire/ -- The number of shares and votes in Immunovia AB (publ) ("Immunovia") have changed as a result of new shares being issued in the rights issue resolved...
► Artikel lesen
Seite:  Weiter >>
31 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1